ATRS Altiris Inc.

Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Antares Pharma, Inc. (ATRS) and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the U.S. District Court for the District of New Jersey on behalf of all persons or entities who purchased or otherwise acquired Antares Pharma, Inc. (NASDAQ:ATRS) securities between December 21, 2016 and October 12, 2017 (the “Class Period”). Investors have until December 22, 2017 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Antares develops pharmaceutical delivery systems, distributes its needle-free injector systems in various countries, and conducts research and development with transdermal gel products. On December 21, 2016, Antares announced its submission of a New Drug Application (“NDA”) for Xyosted to the U.S. Food and Drug Administration (“FDA”). Antares’s product Xyosted has been among its lead product candidates throughout the Class Period.

On October 11, 2017, the Company received a letter from the FDA, stating that the agency had “identified deficiencies that preclude the continuation of the discussion of labeling and post marketing requirements/commitments” for Xyosted.

Following this news, Antares shares fell $1.41 per share, or over 37%, to close at $2.32 per share on October 13, 2017.

On October 20, 2017, Antares announced receipt of a Complete Response Letter from the FDA regarding Xyosted’s NDA. The Company stated that the FDA could not approve the NDA in its present form due to concerns that Xyosted “could cause a clinically meaningful increase in blood pressure” and also noted the FDA’s concerns “regarding the occurrence of depression and suicidality.”

If you purchased or otherwise acquired Antares securities during the Class Period and suffered a loss, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at [email protected], or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information concerning the Antares lawsuit, please go to www.bespc.com/atrs. For additional information about Bragar Eagel & Squire, P.C., please go to www.bespc.com.

EN
01/11/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Altiris Inc.

 PRESS RELEASE

Glancy Prongay & Murray Reminds Investors of the December 22, 2017 Dea...

LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the December 22, 2017 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Antares Pharma, Inc. (“Antares” or the “Company”) (NASDAQ: ATRS) securities between December 21, 2016, and October 12, 2017, inclusive (the “Class Period”). Antares investors have until December 22, 2017 to file a lead plaintiff motion. To obtain information or participate in the class action, please visit the Antare...

 PRESS RELEASE

Scott+Scott, Attorneys at Law, LLP Reminds Investors of December 22nd ...

NEW YORK--(BUSINESS WIRE)-- Scott+Scott, Attorneys at Law, LLP (“Scott+Scott”), a national securities and consumer rights litigation firm, reminds investors that a class action lawsuit has been filed against Antares Pharma, Inc. (NASDAQ: ATRS) (“Antares” or the “Company”) and other defendants, related to alleged violations of federal securities laws. If you purchased Antares securities between December 21, 2016 and October 12, 2017, you are encouraged to a contact a Scott+Scott attorney at (844) 818-6982 for additional informat...

 PRESS RELEASE

DEADLINE ALERT: Brower Piven Reminds Investors Of Upcoming Deadline In...

STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Antares Pharma, Inc. (Nasdaq: ATRS) (“Antares” or the “Company”) securities during the period between December 21, 2016 and October 12, 2017, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until December 22, 2017 to s...

 PRESS RELEASE

The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf...

NEW YORK--(BUSINESS WIRE)-- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Antares Pharma, Inc. (NASDAQ:ATRS) who purchased shares between December 21, 2016 and October 12, 2017. The action, which was filed in the United States District Court for the District of New Jersey, alleges that the Company violated federal securities laws. In particular, the complaint alleges that throughout the Class Period, defendants made materially false and/or misleading statements and/or ...

 PRESS RELEASE

ATRS INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investor...

NEW YORK--(BUSINESS WIRE)-- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Antares Pharma, Inc. ("Antares") (NASDAQ:ATRS) securities between December 21, 2016 and October 12, 2017. Click here to learn about the case: http://www.wongesq.com/pslra-sb/antares-pharma-inc?wire=2. There is no cost or obligation to you. According to the complaint, throughout the Class Period, the C...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch